 |
Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
May 7, 2012
|
8.0 KB |
|
| |
RICHMOND, Calif., May 7, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at the following conferences:
The 11th ...
|
 |
Sangamo BioSciences Reports First Quarter 2012 Financial Results
May 2, 2012
|
16.8 KB |
|
| |
RICHMOND, Calif., May 2, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported first quarter 2012 financial results and accomplishments.
For the first quarter ended March 31, 2012, Sangamo reported a consolidated net loss of $7.3 million, or $0.14 per share, compared to a net loss of $9.6 million, or $0.21 per share, ...
|
 |
Sangamo BioSciences Nominates Saira Ramasastry To The Company's Board Of Directors
Apr 30, 2012
|
11.4 KB |
|
| |
RICHMOND, Calif., April 30, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO), the leader in the development of novel zinc finger DNA-binding proteins (ZFPs) for therapeutic gene modification and regulation, announced today the nomination of Saira Ramasastry to the Company's Board of Directors.
Since April 2009, Ms. Ramasastry ...
|
 |
Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
Apr 25, 2012
|
8.0 KB |
|
| |
RICHMOND, Calif., April 25, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its first quarter 2012 financial results on Wednesday, May 2, 2012, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone a...
|
 |
Sangamo BioSciences Announces Presentation at the Future Leaders in the Biotech Industry Conference
Apr 12, 2012
|
7.6 KB |
|
| |
RICHMOND, Calif., April 12, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 1:30 pm ET on Friday, April 20, 2012, at the...
|
 |
Sangamo BioSciences Announces Publication in Nature Medicine Demonstrating Use of ZFN Technology to Engineer Safer and More Effective Cancer Treatments
Apr 2, 2012
|
11.2 KB |
|
| |
RICHMOND, Calif., April 2, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the publication of a preclinical study demonstrating the use of zinc finger nucleases (ZFNs) to engineer safer and more potent cancer immunotherapies. The study, published in Nature Medicine, advances the development of novel, cell-based therapi...
|
 |
Sangamo BioSciences Announces Presentation at Needham Healthcare Conference
Mar 28, 2012
|
7.6 KB |
|
| |
RICHMOND, Calif., March 28, 2012 /PRNewswire/ --Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 8:40 am ET on Wednesday, April 4, 2012, at th...
|
 |
Sangamo Presents New Clinical Data at CROI 2012 Demonstrating Persistent Positive Effects of ZFN Therapeutic® for "Functional Cure" of HIV/AIDS
Mar 8, 2012
|
17.1 KB |
|
| |
RICHMOND, Calif., March 8, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that new data from its program to develop a 'functional cure' for HIV/AIDS were described in two presentations at the 19th Conference on Retroviruses and Opportunistic Infections (CROI), held in Seattle from March 5 to March 8, 2012.
"These ...
|
 |
Sangamo BioSciences Announces Presentation at 2012 Leerink Swann Global Healthcare Conference
Feb 9, 2012
|
7.5 KB |
|
| |
RICHMOND, Calif., Feb. 9, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 2:30 pm ET on Thursday, February 16, 2012, at ...
|
 |
Sangamo BioSciences Reports Fourth Quarter and Full Year 2011 Financial Results
Feb 8, 2012
|
18.4 KB |
|
| |
RICHMOND, Calif., Feb. 8, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported fourth quarter and full year 2011 financial results and accomplishments.
For the fourth quarter ended December 31, 2011, Sangamo reported a consolidated net loss of $6.4 million, or $0.12 per share, compared to a net loss of $8.3 million, or ...
|
 |
Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
Feb 1, 2012
|
7.9 KB |
|
| |
RICHMOND, Calif., Feb. 1, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its fourth quarter and full year 2011 financial results on Wednesday, February 8, 2012, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the publ...
|
 |
Shire and Sangamo Collaborate to Develop Therapeutics for the Treatment of Hemophilia and Other Monogenic Diseases
Feb 1, 2012
|
12.8 KB |
|
| |
DUBLIN and RICHMOND, Calif., Feb. 1, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, and Sangamo BioSciences, Inc. (NASDAQ: SGMO), a leader in genome-editing technology, announced today that they have entered into a collaboration and license agreement to develop therapeutics for hemophilia a...
|
 |
Sangamo BioSciences Announces Initiation of Two New Phase 2 HIV Clinical Trials
Jan 9, 2012
|
16.9 KB |
|
| |
RICHMOND, Calif., Jan. 9, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the initiation of two new Phase 2 clinical studies (SB-728-1101 and SB-728-902, Cohort 5) in its program to develop a "functional cure" for HIV/AIDS. Sangamo's ZFP Therapeutic® approach (SB-728-T) generates T-cells that are resistant to HIV ...
|
 |
Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
Jan 5, 2012
|
7.5 KB |
|
| |
RICHMOND, Calif., Jan. 5, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 7:30 am PT (10:30 am ET) on Thursday, January ...
|
 |
Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
Dec 13, 2011
|
11.5 KB |
|
| |
RICHMOND, Calif., Dec. 13, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new data demonstrating the ability to permanently correct a disease gene in an adult mouse model of hemophilia B using systemic delivery of zinc finger nucleases (ZFNs) at the 53nd Annual Meeting of the American Society of Hematolo...
|
 |
Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference
Nov 8, 2011
|
7.5 KB |
|
| |
RICHMOND, Calif., Nov. 8, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 11:00 am ET on Tuesday, November 15, 2011 at t...
|
 |
Sangamo BioSciences Reports Third Quarter 2011 Financial Results
Oct 25, 2011
|
16.6 KB |
|
| |
RICHMOND, Calif., Oct. 25, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported third quarter 2011 financial results and accomplishments.
For the third quarter ended September 30, 2011, Sangamo reported a consolidated net loss of $9.6 million, or $0.18 per share, compared to a net loss of $8.7 million, or $0.19 per share...
|
 |
Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
Oct 18, 2011
|
8.0 KB |
|
| |
RICHMOND, Calif., Oct. 18, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its third quarter 2011 financial results on Tuesday, October 25, 2011, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone...
|
 |
Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
Oct 14, 2011
|
7.5 KB |
|
| |
RICHMOND, Calif., Oct. 14, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 9:30 am ET on Friday, October 21, 2011 at the...
|
 |
Sangamo BioSciences Announces Publication in Nature of Gene Correction Strategy for Alpha 1-Antitrypsin Deficiency
Oct 13, 2011
|
11.0 KB |
|
| |
RICHMOND, Calif., Oct. 13, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the publication of a preclinical study demonstrating highly specific, functional correction of the alpha 1-antitrypsin (A1AT) gene defect in patient-derived induced pluripotent stem cells (iPSCs) using zinc finger nucleases (ZFNs). The study, publish...
|
|
|